# Oncologie

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncologie

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.oncologie.international
- Total disclosed funding: $97M
- Latest round: Series B (Jun 10, 2019)
- Investors on record: 6

## About

Oncologie Inc. is a biotechnology company focused on innovative cancer therapies and diagnostic solutions aimed at improving patient outcomes and treatment efficacy.Founded in 2018 and headquartered in Waltham, US, Oncologie Inc. specializes in advancing cancer treatment technologies. The company has secured USD 80.00 mn in Series B funding, led by Nan Fung Life Sciences and Pivotal BioVenture Partners, with new investors such as Korea Investment Partners and Panacea Venture joining the latest funding round on June 10, 2019. The company has completed 2 total deals to date.Oncologie Inc. specializes in groundbreaking technologies for cancer treatment and diagnostics. Their product offerings include innovative therapies designed to improve treatment outcomes for cancer patients. These solutions are developed through rigorous research and address the complexities of cancer management, serving a diverse clientele across North America and Europe.The company generates revenue through a subscription-based model for its proprietary treatment and diagnostic solutions, tailored for various healthcare needs. Additionally, Oncologie Inc. benefits from partnerships that facilitate business-to-business transactions, enhancing their reach in the healthcare sector. Revenue is bolstered by the sale of premium treatment options that allow clients to customize their cancer care strategies.Oncologie Inc. is focused on developing additional cancer therapies set for release in the upcoming years, aiming to enhance its product portfolio significantly. The company plans to expand into new geographic markets throughout Europe and Asia by 2025, leveraging recent funding of USD 80.00 mn to support these initiatives. This funding will be critical in advancing their research and development efforts and enabling them to meet the growing demand for effective cancer treatments.

## Funding rounds

- Series B, Jun 10, 2019, $80M — Korea Investment Partners, Pivotal Life Sciences, Panacea Venture, Nan Fung Life Sciences
- Seed, Jun 7, 2018, $17M — CMB International Asset Management, Pivotal Life Sciences, Volcanics Venture, Nan Fung Life Sciences

## Investors

- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Seed
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Seed, Series B
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Seed
- Nan Fung Life Sciences — Seed, Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series B